Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:fdaapproval_status |
under review
|
| gptkbp:first_described_by |
gptkb:2021
|
| https://www.w3.org/2000/01/rdf-schema#label |
Donanemab
|
| gptkbp:mechanism_of_action |
reduces amyloid plaques
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:structure |
gptkb:Ig_G1
|
| gptkbp:targets |
amyloid beta
|
| gptkbp:used_for |
gptkb:neurodegenerative_diseases
|
| gptkbp:bfsParent |
gptkb:Aducanumab
|
| gptkbp:bfsLayer |
5
|